Related Experiment Video
Updated: Aug 13, 2026
08:15
Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
Diabetic nephropathy: a frontier for personalized medicine
Katalin Susztak1, Erwin P Böttinger
1Division of Nephrology, Department of Medicine, Albert Einstein College of Medicine, New York, New York, USA.
Journal of the American Society of Nephrology : JASN
|January 13, 2006
Summary
Diabetic nephropathy (DNP) is a complex diabetes complication lacking precise risk predictors. New genetic and molecular insights offer hope for early detection and targeted therapies to prevent end-stage renal disease (ESRD).
Area of Science:
- Nephrology
- Diabetology
- Genetics
Background:
- Diabetic nephropathy (DNP) affects one-third of diabetes patients, with variable latency periods.
- Current therapies for DNP are often initiated late and cannot fully prevent end-stage renal disease (ESRD).
- Robust prospective predictors for DNP risk in diabetic individuals remain elusive.
Purpose of the Study:
- To highlight the need for improved predictors of diabetic nephropathy.
- To emphasize the potential of emerging genetic and molecular data for DNP management.
- To bridge the gap between research findings and clinical application in DNP.
Main Methods:
- Analysis of large-scale genetic studies in experimental models and humans.
- Validation of molecular mRNA profiles from microarray screens.
- Refinement of genetic loci associated with albuminuria and diabetic kidney disease progression.
Main Results:
- Identification of genetic factors influencing DNP susceptibility and progression.
- Emerging molecular markers from mRNA profiles show potential for early detection.
- New molecular insights into DNP pathogenesis are rapidly advancing.
Conclusions:
- Translating genetic and molecular data is crucial for developing reliable DNP predictors.
- Improved predictors will enhance clinical trial design and individualized patient management.
- The ultimate goal is to prevent ESRD and improve outcomes for millions with diabetes.
Related Concept Videos
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...